+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a new approach to prevent and reduce agitation and the use of physical restraints in adult patients in intensive care units ICUs. This study compares a person-centered multicomponent intervention program that includes non-drug methods combined with goal-directed light sedation using dexmedetomidine against the usual care that often involves physical restraints. The goal is to see how these approaches affect both short- and long-term patient outcomes and healthcare costs. The study involves two groups one receiving the multicomponent intervention combining non-pharmacological strategies and dexmedetomidine sedation when needed, and the other receiving standard care that may include physical restraints. The intervention aims to reduce agitation and minimize restraint use during the ICU stay. Participants are adult ICU patients expected to stay more than 24 hours and at risk of becoming agitated within their first two weeks in the ICU. Participants will be monitored for up to 28 days to measure ICU-free days as the main outcome. Additional assessments include rates of accidental device removal, reintubations, days with delirium or coma, use of physical restraints and sedatives, duration of mechanical ventilation, hospital stay length, mortality at various time points, and physical, mental, cognitive, and quality of life outcomes up to 24 months. Safety events related to dexmedetomidine are also tracked. Follow-up includes long-term monitoring for up to two years to evaluate the lasting effects of the interventions.

Age: 18Years +All GendersPhase Not Applicable
5 locations
P

Actively Recruiting

This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.

Age: 18Years +All GendersPhase 3
306 locations